公开(公告)号：US20240360206A1

公开(公告)日：2024-10-31

申请号：US18770102

申请日：2024-07-11

Applicant: ALZPATH, INC.

Inventor： Andreas Jeromin ,  Krish Venkat

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/20 ,  C07K2317/24

Abstract: Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

公开(公告)号：US20240358805A1

公开(公告)日：2024-10-31

申请号：US18688269

申请日：2022-08-30

Applicant: The Brigham and Women's Hospital, Inc. ,  Abyssinia Biologics, LLC

Inventor： Dennis J. Selkoe ,  Lei Liu ,  Robert Leslie Lawton

IPC: A61K39/00 ,  A61P25/28 ,  C07K16/18 ,  G01N33/68

CPC classification number: A61K39/0007 ,  A61P25/28 ,  C07K16/18 ,  G01N33/6896 ,  A61K2039/6081 ,  G01N2800/2821

Abstract: Described herein are methods for making and using antibodies that bind specifically to soluble oligomers of amyloid beta protein (oAβ), and methods of use thereof in diagnosis and treatment of diseases related to formation of pathogenic oligomers of oAβ. Also provided are T helper cell (Th) carrier peptides that can be conjugated to peptide immunogens to stimulate targeted humoral immune responses to the desired antigen.

公开(公告)号：US12129291B2

公开(公告)日：2024-10-29

申请号：US18335477

申请日：2023-06-15

Applicant: Yamaguchi University ,  National Cancer Center ,  Noile-Immune Biotech, Inc.

Inventor： Koji Tamada ,  Yukimi Sakoda ,  Tetsuya Nakatsura ,  Keigo Saito

IPC: C07K16/18 ,  C07K14/54 ,  C07K14/725 ,  C07K16/30 ,  C12N5/078 ,  C12N5/0783 ,  G01N33/68

CPC classification number: C07K16/18 ,  C07K14/5418 ,  C07K14/7051 ,  C07K16/303 ,  C12N5/0634 ,  C12N5/0636 ,  G01N33/68 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

公开(公告)号：US12128101B2

公开(公告)日：2024-10-29

申请号：US16757512

申请日：2018-10-26

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Lori Payton ,  Scott T. Rottinghaus ,  Rajendra Pradhan ,  Andrew Damokosh ,  Xiang Gao

IPC: A61K39/395 ,  A61K9/00 ,  A61K39/00 ,  A61P7/00 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61P7/00 ,  C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.

公开(公告)号：US20240352108A1

公开(公告)日：2024-10-24

申请号：US18686099

申请日：2022-08-24

Applicant: IMMUNEMED INC.

Inventor： Mi-La CHO ,  Seon-Yeong LEE ,  Aram LEE ,  Jeong-Won CHOI ,  Yoon-Won KIM ,  Sungnam PARK ,  Byung-Cheol LEE ,  Ah-Lum LEE

IPC: C07K16/18 ,  A61K39/00 ,  A61P19/02 ,  A61P37/06 ,  G01N33/564

CPC classification number: C07K16/18 ,  A61P19/02 ,  A61P37/06 ,  G01N33/564 ,  A61K2039/505 ,  C07K2317/76 ,  G01N2800/102

Abstract: The present invention relates to a selective immunomodulatory target antibody drug composition for prevention or treatment of autoimmune diseases. An anti-vimentin antibody of the present invention has the effects of inhibiting synovial tissue destruction and cartilage damage in rheumatoid arthritis and in intractable rheumatoid arthritis caused by obesity, specifically binding to both vimentin protein in serum and joint tissues and citrullinated vimentin protein and blocking same, and inhibiting etiological immune cells and thus the antibody can be effectively used for preventing or treating autoimmune diseases including rheumatoid arthritis.

公开(公告)号：US20240352107A1

公开(公告)日：2024-10-24

申请号：US18685718

申请日：2022-09-15

Applicant: H. LUNDBECK A/S

Inventor： Roger K. CADY ,  Joseph HIRMAN ,  Carlton ANDERSON ,  Elizabeth BRUNNER

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/06

CPC classification number: C07K16/18 ,  A61P25/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

Abstract: The present invention relates the use of monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibodies or anti-CGRP receptor antibodies in subjects that do not respond adequately to a first dose but respond to the second dose.

公开(公告)号：US20240352104A1

公开(公告)日：2024-10-24

申请号：US18627655

申请日：2024-04-05

Applicant: Agency for Science, Technology and Research

Inventor： Frederic Bard ,  Anh Tuan Nguyen ,  Ros Manon

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622

Abstract: We describe a Cnx/ERp57 inhibitor for use in the treatment or prevention of cancer.

公开(公告)号：US20240352100A1

公开(公告)日：2024-10-24

申请号：US18290613

申请日：2022-07-20

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Yong Sung KIM ,  Dasom LEE ,  Jisu SEO ,  Hae Jin KWEON ,  Dae-Seong KIM

IPC: C07K16/18 ,  C12N15/63

CPC classification number: C07K16/18 ,  C12N15/63 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2319/00

Abstract: A cell-penetrating degrading antibody is disclosed. In the cell-penetrating degrading antibody, U-Box of E3 that can bind to E2 of an ubiquitin-proteasome system (UPS), which is an intracellular protein degradation system, or an E3 recruiter (E3 recruiting ligand) that can bind to E3 of the UPS is fused to a cell-penetrating interfering antibody that penetrates into the cytosol of living cells and specifically recognizes a target protein. A composition containing the cell-penetrating antibody and uses thereof are disclosed.

公开(公告)号：US20240352083A1

公开(公告)日：2024-10-24

申请号：US18647911

申请日：2024-04-26

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K14/54 ,  C07K14/505 ,  C07K14/535 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US20240350669A1

公开(公告)日：2024-10-24

申请号：US18762799

申请日：2024-07-03

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Stavroula KOUSTENI ,  Marta GALÁN-DÍEZ

IPC: A61K48/00 ,  A61K31/4245 ,  A61P35/02 ,  C07K16/18 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113

CPC classification number: A61K48/005 ,  A61K31/4245 ,  A61P35/02 ,  C07K16/18 ,  C12N9/22 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/20 ,  C12Y113/11052

Abstract: Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. The inhibitor can be a small molecule such as indiximod, epacadostat, BMS-986205, navoximod, PF-0684003, KHK2455 or LY3381916 or epacadostat. The inhibitor can be used alone or in conjunctions with other chemotherapeutic agents. IDO1 can also be inhibited using a CRISP-CAS system. The inhibitor can be administered orally, intravenously, intramuscularly, topically, arterially, or subcutaneously.